The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.

Full Story →

The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.

Full Story →

The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.

Full Story →

The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.

Full Story →

The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.

Full Story →

The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.

Full Story →

The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.

Full Story →